Cardiovascular diseases (CVD) are the leading cause of death worldwide, accounting for over 17 million death each year. Environmental and genetic factors contribute to a dramatic increase in the number of people affected by such conditions in the coming years. The study of these diseases is of fundamental importance for developing appropriate treatments. These conditions are primarily treated using surgical approaches, pharmacological approaches, or often by combining both. To develop effective pharmacological treatments that maximize therapeutic action, it is necessary to study these diseases; this process is known as drug screening. The drug screening process involves various stages to ensure that the drug can be marketed and that it has an actual therapeutic effect.